Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study.

In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has demonstrated efficacy in the treatment of advanced RCC. Our study aimed to evaluate the efficacy and safety in the neoadjuvant therapy setting of tislelizumab and axitinib in RCC patients with IVC tumor thrombus.

Label-free plasmonic metasensing of PSA and exosomes in serum for rapid high-sensitivity diagnosis of early prostate cancer.

Prostate-specific antigen (PSA) test is widely used to diagnose early prostate cancer (PCa). Its low sensitivity, especially in the gray zone, usually incurs overtreatment or missed diagnosis. As an emerging tumor marker, exosomes have attracted great interest in non-invasive diagnosis of PCa.

Development of Co-based bulk metallic glasses as potential biomaterials.

A new series of Co80-x-yCrxMoyP14B6 (x=5 y=5; x=5 y=10; x=10 y=10, all values in at.%) bulk metallic glasses (BMGs) with a maximum diameter of 1.5mm has been developed for using them as potential bio-implant materials by a combination of fluxing treatment and J-quenching technique.

Development of Fe-based bulk metallic glasses as potential biomaterials.

A new series of Fe80-x-yCrxMoyP13C7 (x = 10, y = 10; x = 20, y = 5; x = 2 0, y = 10, all in at.%) bulk metallic glasses (BMGs) with the maximum diameter of 6mm have been developed for biomedical implant application by the combination method of fluxing treatment and J-quenching technique. The corrosion performance of the present Fe-based BMGs is investigated in both Hank's solution (pH = 7.